90 related articles for article (PubMed ID: 15128353)
1. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
Formann E; Stauber R; Denk DM; Jessner W; Zollner G; Munda-Steindl P; Gangl A; Ferenci P
Am J Gastroenterol; 2004 May; 99(5):873-7. PubMed ID: 15128353
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
4. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment.
Elloumi H; Houissa F; Hadj NB; Gargouri D; Romani M; Kharrat J; Ghorbel A
World J Gastroenterol; 2007 Oct; 13(40):5411-2. PubMed ID: 17879419
[TBL] [Abstract][Full Text] [Related]
5. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Berg T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2001 Feb; 39(2):145-51. PubMed ID: 11253505
[TBL] [Abstract][Full Text] [Related]
7. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
[TBL] [Abstract][Full Text] [Related]
8. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
9. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
Jacobson IM; Ahmed F; Russo MW; Lebovics E; Dieterich DT; Esposito SP; Bach N; Klion F; Tobias H; Antignano L; Brown RS; Gabbaizadeh D; Geders J; Levendoglu H
Am J Gastroenterol; 2004 Sep; 99(9):1700-5. PubMed ID: 15330905
[TBL] [Abstract][Full Text] [Related]
10. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C.
Khalili M; Denham C; Perrillo R
Am J Gastroenterol; 2000 May; 95(5):1284-9. PubMed ID: 10811340
[TBL] [Abstract][Full Text] [Related]
11. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
Jara P; Hierro L; de la Vega A; Díaz C; Camarena C; Frauca E; Miños-Bartolo G; Díez-Dorado R; de Guevara CL; Larrauri J; Rueda M
Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil.
Mendes-Corrêa MC; Bittar RS; Salmito N; Oiticica J
Braz J Infect Dis; 2011; 15(1):87-9. PubMed ID: 21412597
[TBL] [Abstract][Full Text] [Related]
16. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
17. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
18. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
Zilly M; Lingenauber C; Desch S; Väth T; Klinker H; Langmann P
Eur J Med Res; 2002 Apr; 7(4):149-54. PubMed ID: 12010649
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient.
Johnson K; Sargent LA; Galizio C; Ubogu EE
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1110-4. PubMed ID: 19047844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
